Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.
Evotec SE (NASDAQ: EVO; Frankfurt: EVT) is a life science company focused on drug discovery and development, and its news flow reflects ongoing activity across partnerships, platforms and biologics. Company updates frequently highlight progress in strategic collaborations, such as multi-target kidney disease programs with Bayer, protein degradation and neuroscience alliances with Bristol Myers Squibb, and technology-focused agreements with Sandoz.
Investors following EVO news can expect announcements on clinical and preclinical milestones, including the advancement of monoclonal antibody programs into Phase 2 trials and Investigational New Drug acceptances for molecular glue degraders. Evotec also reports on grants and global health initiatives, for example Gates Foundation support for Just - Evotec Biologics’ J.MD™ molecular design service to improve the developability and affordability of monoclonal antibodies for infectious diseases.
News from Just - Evotec Biologics often centers on biologics development, continuous manufacturing technologies and the evolution of its asset-lighter model. This includes transactions such as the sale of the Toulouse site to Sandoz combined with an indefinite license to Evotec’s continuous manufacturing platform, as well as updates on revenue growth with a broadened customer base.
Regular corporate communications also cover financial results, guidance updates, cost reduction initiatives and organizational changes, such as segment renaming to Discovery & Preclinical Development and senior leadership appointments in communications and investor relations. For readers tracking EVO stock, this news page provides a consolidated view of how Evotec’s partnerships, platforms and strategic transactions are progressing over time.
Evotec SE (NASDAQ:EVO) has revised its revenue guidance for fiscal year 2025 while maintaining its profit outlook. The company now expects group revenues of €760-800 million, down from the previous guidance of €840-880 million. Despite lower revenue projections, Evotec maintains its adjusted EBITDA guidance of €30-50 million and R&D expenditure forecast of €40-50 million.
The guidance adjustment reflects a shift in revenue mix and successful cost-saving initiatives from the Priority Reset program. While technology licensing is showing stronger performance, the Shared R&D base business faces challenging market conditions. First-half 2025 revenues were below expectations, though adjusted EBITDA remained aligned with projections.
Evotec SE (NASDAQ:EVO) has joined the NURTuRE-AKI consortium to study acute kidney injury (AKI) through a comprehensive patient cohort study. The initiative will collect longitudinal data and biological samples from three key patient groups: iatrogenic AKI following cardiac surgery, AKI to chronic kidney disease transition, and pediatric AKI.
The study will integrate with Evotec's Molecular Patient Database (E.MPD), conducting state-of-the-art omics analyses on blood, urine, and research biopsy samples. This collaboration aims to identify novel therapeutic targets and biomarkers for AKI treatment, addressing a significant unmet medical need.
Evotec SE (NASDAQ: EVO) has secured a $2.5 million grant from The Gates Foundation to advance the development of next-generation tuberculosis (TB) treatment regimens. This marks the second grant from the foundation focused on evaluating improved TB therapies using Evotec's translational platforms.
The new funding extends a successful five-year partnership that has already produced standardized preclinical data for selecting shorter, safer, and more effective TB drug combinations. Evotec will utilize its integrated TB platform to further characterize promising treatment regimens, aiming to accelerate the development of transformative TB treatments.
Evotec SE has scheduled the announcement of its first quarter 2025 financial results for Tuesday, May 6, 2025. The company will host a conference call and webcast to discuss the quarterly performance and provide business updates.
The event details include:
- Date: Tuesday, May 6, 2025
- Time: 2:00 PM CEST (1:00 PM BST, 8:00 AM EDT)
- Format: Audio webcast with presentation slides
- Language: English
Participants can join via web or phone, with pre-registration required for dial-in access. The presentation will be available simultaneously for phone participants, and an on-demand version will be accessible through Evotec's website under Financial Publications.
Evotec SE (NASDAQ:EVO) has announced significant progress in its strategic research collaboration with Bristol Myers Squibb, triggering total payments of US$ 75 million to Evotec through performance-based and program-based achievements.
The collaboration, initiated in 2018 and expanded in 2022, combines Evotec's high-performance multi-omics screening and AI-supported data analytics with Bristol Myers Squibb's cereblon E3 ligase modulators (CELMoDs™) library. The partnership focuses on developing molecular glue degraders for high-value targets in oncology and other therapeutic areas.
The collaboration continues to advance its pipeline of molecular degraders, aiming to deliver multiple first-in-class products to market for unmet medical needs.
Evotec SE (NASDAQ:EVO) has announced its FY 2024 results and unveiled a new strategic direction focused on drug discovery and biologics. The company reported a 2% revenue increase to €797.0 million, with Q4 2024 revenues up 10% to €221.2 million.
Key highlights include:
- Just - Evotec Biologics segment grew 71% year-over-year to €185.6 million
- Adjusted Group EBITDA reached €22.6 million
- Priority Reset program on track to deliver €40 million in annual savings
- Net debt leverage ratio improved to 1.9x
For 2025 guidance, Evotec expects:
- Revenue range of €840-880 million
- R&D expenditure of €40-50 million
- Adjusted Group EBITDA of €30-50 million
The company's 2028 outlook targets revenue CAGR of 8-12% (2024-2028) and adjusted EBITDA margin above 20%.
Evotec SE (NASDAQ: EVO) has scheduled the announcement of its financial year 2024 results for Thursday, April 17, 2025. The company will host a conference call at 2:00 PM CEST (1:00 PM BST, 8:00 AM ET) to discuss the results and provide updates on their concluded strategic review process.
The presentation will be conducted in English and will be accessible via both webcast and phone conference. Participants joining via phone must pre-register to receive dedicated dial-in details. The company will make an on-demand version of the webcast available on their website following the presentation.
Evotec SE (NASDAQ:EVO) has achieved a significant milestone in its neuroscience collaboration with Bristol Myers Squibb, triggering a $20 million research payment. The achievement relates to advancing a promising pre-clinical programme in neurodegeneration.
The strategic partnership, initiated in December 2016, focuses on developing disease-modifying treatments for neurodegenerative diseases, moving beyond current symptom management approaches. Notable successes include the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021.
In March 2023, both companies extended their collaboration for an additional eight years, demonstrating their commitment to developing breakthrough therapies for neurological diseases.
Evotec SE (NASDAQ:EVO) announced a significant leadership change as Chief Financial Officer Laetitia Rouxel will step down effective February 28, 2025, and leave the company by March 31, 2025. Paul Hitchin has been appointed as the new CFO, effective March 1, 2025.
Hitchin brings over 20 years of finance leadership experience, most recently serving as CFO at Mediq where he led business growth and transformation initiatives. His previous roles include 13 years at General Electric, including 5 years with GE Healthcare. The company emphasized that Hitchin's financial expertise and transformation experience will be important for Evotec's strategic journey toward profitable and sustainable growth.